Clinical Trial: Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07160686) titled 'Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment' on July 29.

Brief Summary: The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming.

The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.

Participants will receive the following treatment:

* Apixaban or placebo, 2.5mg taken by mouth twice a day for...